PD0332991, a cdk4/6 INHIBITOR, INDUCES TUMOR REGRESSION AND EXTENDS SURVIVAL IN ATYPICAL TERATOID RHABDOID TUMOR (ATRT) AND MEDULLOBLASTOMA MOUSE MODELS

被引：0
|
作者：
Sangar, Michelle Cook [1 ]
Pedro, Kyle [1 ]
Ditzler, Sally H. [1 ]
Girard, Emily [1 ]
Olson, James [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
来源：
NEURO-ONCOLOGY | 2013年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0151
引用
收藏
页码：40 / 41
页数：2
相关论文
共 40 条
  • [1] Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
    Leonard, John P.
    LaCasce, Ann S.
    Smith, Mitchell R.
    Noy, Ariela
    Chirieac, Lucian R.
    Rodig, Scott J.
    Yu, Jian Q.
    Vallabhajosula, Shankar
    Schoder, Heiko
    English, Patricia
    Neuberg, Donna S.
    Martin, Peter
    Millenson, Michael M.
    Ely, Scott A.
    Courtney, Rachel
    Shaik, Naveed
    Wilner, Keith D.
    Randolph, Sophia
    Van den Abbeele, Annick D.
    Chen-Kiang, Selina Y.
    Yap, Jeffrey T.
    Shapiro, Geoffrey I.
    BLOOD, 2012, 119 (20) : 4597 - 4607
  • [2] The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
    Paternot, Sabine
    Colleoni, Bianca
    Bisteau, Xavier
    Roger, Pierre P.
    CELL CYCLE, 2014, 13 (18) : 2879 - 2888
  • [3] Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth
    Hashizume, Rintaro
    Zhang, Ali
    Mueller, Sabine
    Prados, Michael D.
    Lulla, Rishi R.
    Goldman, Stewart
    Saratsis, Amanda M.
    Mazar, Andrew P.
    Stegh, Alexander H.
    Cheng, Shi-Yuan
    Horbinski, Craig
    Haas-Kogan, Daphne A.
    Sarkaria, Jann N.
    Waldman, Todd
    James, C. David
    NEURO-ONCOLOGY, 2016, 18 (11) : 1519 - 1528
  • [4] The CDK4/6 Inhibitor PD0332991 Reverses Epithelial Dysplasia Associated with Abnormal Activation of the Cyclin-CDK-Rb Pathway
    Cabrera, M. Carla
    Diaz-Cruz, Edgar S.
    Kallakury, Bhaskar V. S.
    Pishvaian, Michael J.
    Grubbs, Clinton J.
    Muccio, Donald D.
    Furth, Priscilla A.
    CANCER PREVENTION RESEARCH, 2012, 5 (06) : 810 - 821
  • [5] Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia
    Nemoto, Atsushi
    Saida, Satoshi
    Kato, Itaru
    Kikuchi, Jiro
    Furukawa, Yusuke
    Maeda, Yasuhiro
    Akahane, Koshi
    Honna-Oshiro, Hiroko
    Goi, Kumiko
    Kagami, Keiko
    Kimura, Shinya
    Sato, Yuko
    Okabe, Seiichi
    Niwa, Akira
    Watanabe, Kenichiro
    Nakahata, Tatsutoshi
    Heike, Toshio
    Sugita, Kanji
    Inukai, Takeshi
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (01) : 94 - 105
  • [6] Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models
    Sangar, Michelle L. Cook
    Genovesi, Laura A.
    Nakamoto, Madison W.
    Davis, Melissa J.
    Knobluagh, Sue E.
    Ji, Pengxiang
    Millar, Amanda
    Wainwright, Brandon J.
    Olson, James M.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5802 - 5813
  • [7] PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
    Barton, Kelly L.
    Misuraca, Katherine
    Cordero, Francisco
    Dobrikova, Elena
    Min, Hooney D.
    Gromeier, Matthias
    Kirsch, David G.
    Becher, Oren J.
    PLOS ONE, 2013, 8 (10):
  • [8] PD-0332991, A CDK4/6 INHIBITOR, SIGNIFICANTLY PROLONGS SURVIVAL IN A GENETICALLY ENGINEERED MOUSE MODEL OF BRAINSTEM GLIOMA
    Barton, Kelly
    Misuraca, Katie
    Cordero, Francisco
    Dobrikova, Elena
    Min, Hooney
    Gromeier, Matthias
    Kirsch, David
    Becher, Oren
    NEURO-ONCOLOGY, 2013, 15 : 38 - 38
  • [9] The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma
    Zhang, Bin
    Li, Dan
    Jin, Xin
    Zhang, Kun
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2020, 128
  • [10] Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models
    Sorrentino, J.
    Bisi, J.
    Thompson, D.
    Lai, A.
    Strum, J.
    Roberts, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E47 - E48
1234